HZNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Horizon Pharma PLC's quarterly additional paid-in capital increased from Dec. 2015 ($2,001.6 Mil) to Mar. 2016 ($2,026.0 Mil) and increased from Mar. 2016 ($2,026.0 Mil) to Jun. 2016 ($2,057.1 Mil).
Horizon Pharma PLC's annual additional paid-in capital increased from Dec. 2013 ($410.4 Mil) to Dec. 2014 ($1,269.9 Mil) and increased from Dec. 2014 ($1,269.9 Mil) to Dec. 2015 ($2,001.6 Mil).
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
|Additional Paid-In Capital||=||(Issue Price||-||Par Value)||*||Shares Outstanding|
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Horizon Pharma PLC Annual Data
Horizon Pharma PLC Quarterly Data